Abstract:Objective To study the effects of caffeine citrate on myelin basic protein (MBP) expression in the cerebral white matter of neonatal rats with hypoxic-ischemic brain damage (HIBD) and the related mechanism.Methods Forty-eight seven-day-old Sprague-Dawley neonatal rats were randomly assigned to 3 groups:sham operation (n=16), HIBD (n=16) and HIBD+caffeine citrate (n=16). The rats in the HIBD and HIBD+caffeine citrate groups were subjected to left common carotid artery ligation, and then were exposed to 80 mL/L oxygen and 920 mL/L nitrogen for 2 hours to induce HIBD. The rats in the sham operation group were only subjected to a sham operation, without the left common carotid artery ligation or hypoxia exposure. Caffeine citrate (20 mg/kg) was injected intraperitoneally before hypoxia ischemia (HI) and immediately, 24 hours, 48 hours and 72 hours after HI. The other two groups were injected intraperitoneally with an equal volume of normal saline at the corresponding time points. On postnatal day 12, the expression of MBP in the left subcortical white matter was detected by immunohistochemistry, and the levels of adenosine A1 receptor mRNA and A2a receptor mRNA in the left brain were detected by real-time PCR.Results The expression of MBP in the left subcortical white matter in the HIBD group was lower than in the sham operation group (PPPConclusions Caffeine citrate can improve brain white matter damage following HIBD in neonatal rats and the protection mechanism might be related with the down-regulation of adenosine A1 receptor expression.
XU Fa-Lin,CHENG Hui-Qing,WANG Cai-Hong et al. Effects of caffeine citrate on myelin basic protein in neonatal rats with hypoxicischemic brain damage[J]. CJCP, 2015, 17(9): 984-988.
Kreutzer K, Bassler D. Caffeine for apnea of prematurity:a neonatal success story[J]. Neonatology, 2014, 105(4):332-336.
[2]
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2007, 357(19):1893-1902.
[3]
Doyle LW, Cheong J, Hunt RW, et al. Caffeine and brain development in very preterm infants[J]. Ann Neurol, 2010, 68(5):734-742.
[4]
Doyle LW, Schmidt B, Anderson PJ, et al. Reduction in developmental coordination disorder with neonatal caffeine therapy[J]. Pediatrics, 2014, 165(2):356-359.
[5]
Kilicdag H, Daglioglu YK, Erdogan S, et al. Effects of caffeine on neuronal apoptosis in neonatal hypoxicischemic brain injury[J]. J Matern Fetal Neonatal Med, 2014, 27(14):1470-1475.
[6]
Gervitz LM, Lutherer LO, Davies DG, et al. Adenine induces initial hypoxic-ischemic depression of synaptic transmission in the rat hippocampus in vivo[J]. Am J Physiol Regul Integr Comp Physiol, 2001, 280(3):R639-R645.
[7]
Alexander M, Smith AL, Rosenkrantz TS, et al. Therapeutic effect of caffeine treatment immediately following neonatal hypoxic-ischemic injury on spatial memory in male rats[J]. Brain Sci, 2013, 3(1):177-190.
[8]
Favrais G, Tourneux P, Lopez E, et al. Impact of common treatments given in the perinatal period on the developing brain[J]. Neonatology, 2014, 106(3):163-172.
[9]
Gieron-Korthals M, Colon J. Hypoxic-ischemic encephalopathy ininfants:new challenges[J]. Fetal Pediatr Pathol, 2005, 24(2):105-120.
[10]
Rice JE 3rd, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat[J]. Ann Neurol, 1981, 9(2):131-141.
[11]
Back SA, Craig A, Luo NL, et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury[J]. Ann Neurol, 2006, 60(6):696-705.
[12]
Atik A, Cheong J, Harding R, et al. Impact of daily high-dose caffeine exposure on developing white matter of the immature ovine brain[J]. Pediatr Res, 2014, 76(1):54-63.
[13]
Albertsson AM, Bi D, Duan L, et al. The immune response after hypoxia-ischemia in a mouse model of preterm brain injury[J]. J Neuroinflammation, 2014, 11:153.
Solinas M, Ferre S, Antoniou K, et al. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats[J]. Psychopharmacology (Berl), 2005, 179(3):576-586.
[16]
Rivkees SA, Thevananther S, Hao H. Are A3 adenosine receptors expressed in the brain?[J]. Neuroreport, 2000, 11(5):1025-1030.
[17]
Stehle JH, Rivkees SA, Lee JJ, et al. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype[J]. Mol Endocrinol, 1992, 6(3):384-393.
[18]
Rivkees SA. The ontogeny of cardiac and neural A1 adenosine receptor expression in rats[J]. Brain Res Dev Brain Res, 1995, 89(2):202-213.
[19]
Swanson TH, Drazba JA, Rivkees SA. Adenosine A1 receptors are located predominantly on axons in the rat hippocampal formation[J]. J Comp Neurol, 1995, 363(4):517-531.
[20]
Fredholm BB. Adenosine and neuroprotection[J]. Int Rev Neurobiol, 1997, 40:259-280.
[21]
Turner CP, Yan H, Schwartz M, et al. A1 Adenosine receptor activation induces ventrilomegaly and white matter loss[J]. Neuroreport, 2002, 13(9):1199-1204.
[22]
Cunha RA. Neuroprotection by adenosine in the brain:From A(1) receptor activation to A (2A) receptor blockade[J]. Purinergic Signal, 2005, 1(2):111-134.
[23]
Rivkees SA, Zhao Z, Porter G, et al. Influences of adenosine on the fetus and newborn[J]. Mol Genet Metab, 2001, 74(1-2):160-171.
[24]
Chavez Valdez R, Ahlawat R, Wills-Karp M, et al. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants[J]. J Pediatr, 2011, 158(1):57-64.
[25]
Kumral A, Yesilirmak DC, Aykan S, et al. Protective effects of methylxanthines on hypoxia-induced apoptotic neurodegeneration and long-term cognitivefunctions in the developing rat brain[J]. Neonatology, 2010, 98(2):128-136.